Treg dysfunction is a well-established feature across autoimmune diseases and therapeutic strategies such as low-dose IL-2 have been shown promising in selectively expanding functional Tregs and restoring immune tolerance in early-phase clinical trials [66, 67]. This evidence concerns the gene IL2 and autoimmune disease.